| Pioneer of prostate cancer: past, present and the future of FOXA1 M Teng, S Zhou, C Cai, M Lupien, HH He Protein & Cell 12 (1), 29-38, 2021 | 121 | 2021 |
| Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer S Zhou, JR Hawley, F Soares, G Grillo, M Teng, SA Madani Tonekaboni, ... Nature communications 11 (1), 441, 2020 | 78 | 2020 |
| MiR-34c downregulation leads to SOX4 overexpression and cisplatin resistance in nasopharyngeal carcinoma PA Bissey, M Teng, JH Law, W Shi, JP Bruce, V Petit, SW Tsao, KW Yip, ... BMC cancer 20, 1-13, 2020 | 26 | 2020 |
| Functional cooperativity between the trigger factor chaperone and the ClpXP proteolytic complex K Rizzolo, AYH Yu, A Ologbenla, SR Kim, H Zhu, K Ishimori, G Thibault, ... Nature communications 12 (1), 281, 2021 | 25 | 2021 |
| Transposable elements are co-opted as oncogenic regulatory elements by lineage-specific transcription factors in prostate cancer G Grillo, T Keshavarzian, S Linder, C Arlidge, L Mout, A Nand, M Teng, ... Cancer discovery 13 (11), 2470-2487, 2023 | 17 | 2023 |
| Assembling the RNA therapeutics toolbox M Teng, ZJ Xia, N Lo, K Daud, HH He Medical Review 4 (2), 110-128, 2024 | 2 | 2024 |
| In vivo CRISPR screens identify a dual function of MEN1 in regulating tumor–microenvironment interactions P Su, Y Liu, T Chen, Y Xue, Y Zeng, G Zhu, S Chen, M Teng, X Ci, M Guo, ... Nature Genetics 56 (9), 1890-1902, 2024 | 1 | 2024 |
| Orphan noncoding RNAs: novel regulators and cancer biomarkers M Teng, LY Liu, JT Hua, S Chen, HH He Annals of Translational Medicine 7 (Suppl 1), 2019 | 1 | 2019 |
